- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01241643
Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders (Inspire 3)
A Multicenter, Open-labeled, Controlled, Randomized Study of Recombinant Interleukin-7 (CYT107) Treatment to Restore and Maintain CD4 T-lymphocyte Counts Above 500 Cells/µL in HIV-infected Patients With CD4 Counts Remaining Between 101-350 Cells/µL After at Least 2 Years of HAART and Plasma HIV RNA < 50 Copies/mL for 18 Months.
Study Overview
Detailed Description
The aim of the study is to assess repeated cycles of 3 weekly injections of CYT107 in patients immune non-responders infected with HIV.
Eighty patients will be recruited to study the biological activity and safety of repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months. The entire study will cover a period of 24 months.
During the study visits the following may be done:
- medical history, physical examination, blood test every visit
- EKG
- chest X-Ray
- liver/spleen ultrasound
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Milano, Italy
- San Raffaele Scientific Institute
-
-
-
-
-
Johannesbourg, South Africa, 2092
- Helen Joseph Hospital-Themba Lethu Clinic
-
-
-
-
-
Zurich, Switzerland, 8091
- University of Zurich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-1 infection as documented by any licensed ELISA (Enzyme-Linked Immunosorbent Assay) test kit and confirmed either by Western Blot or a 2nd test using a different method at any time prior to study entry
- Age ≥18
- On HAART (Highly active anti-retroviral therapy) for at least 24 months, on stable regimen for at least 6 months prior to study entry. HAART is defined as a combination of two (2) classes dose regimen of approved ARV (antiretroviral)
- CD4+ cell counts ≥ 101 and < 350 cells/µL measured on at least two (2) measurements (including the screening value) within the previous 12 months prior to study entry Note: a single isolated value of CD4+ ≥ 350 during this period (12 months prior to study entry) will be allowed to participate if the previous and subsequent CD4+ count is in the range of ≥ 101 and < 350 cells/µL
- Plasma HIV RNA < 50 copies/mL since at least 18 months with at least two (2) measurements (including the screening value) within the previous 6 months prior study entry Note: patients with single blip of detectable viremia during this period (6 months prior to study entry) will be allowed to participate if the prior and subsequent plasma HIV RNA levels are < 50 copies/mL
Adequate bone marrow, hepatic and renal function as follows:
- Hemoglobin ≥ 10 g/dl
- Neutrophils ≥ 1,000/µL
- Platelets ≥ 100,000/µL
- AST, ALT, or Alk. Phosph. ≤ 2.5 x ULN
- Total Bilirubin ≤ 1.5 x ULN (or ≤ 5 x ULN if the patient is treated by atazanavir or by indinavir, and if the increase is due to unconjugated bilirubin and if ALT and AST are normal)
- Lipase ≤ 2 x ULN
- PT/PTT ≤ 1.5 x ULN
- Estimated glomerular filtration ≥ 60 ml/min (according to MDRD formula)
- Normal blood Thyroid-Stimulating Hormone (TSH)
- Ability to understand and sign informed consent
Exclusion Criteria:
- AIDS-defining illness (category C) diagnosed within the last 12 months prior to study entry
- History of HIV related encephalopathy
- Active opportunistic infection including active tuberculosis
- Previous treatment with IL-2 or IL-7 at any time prior to study entry
- Any planned or probable modification of the anti-retroviral treatment during the first year or the first two cycles of CYT107 Note: in case of product shortage and in absence of viral mutation suspicion or viral blip, a modification of ARV will not be an exclusion criterion
- Poor compliance on HAART or any other chronic treatment that in the opinion of the investigator will interfere with protocol participation
- Previous treatment with immuno-modulatory agents such as, systemic corticosteroids, growth factors, immunosuppressive drugs, HIV vaccine, or anti-cancer treatment or hydroxyurea within 3 months prior to study entry
- Any history of malignancy (except basal carcinoma of the skin) including any hematologic malignancy or AIDS defining malignancy, such as lymphoproliferative disorder or Kaposi's sarcoma Note: Patients with Kaposi's sarcoma limited to the skin that had disappeared while on HAART therapy, and without requiring any other systemic therapy 1 year prior to study entry, will be eligible.
- Any history of severe auto-immune disease requiring systemic treatment or hospitalization, or any active auto-immune disease requiring treatment (including multiple sclerosis)
- History of splenectomy
- Any hematologic disease associated with hypersplenism, such as thalassemia, hereditary spherocytosis, Gaucher's Disease, and autoimmune hemolytic anemia
- Chronic hepatitis B or C
- HIV-2, HTLV-1 or HTLV-2 seropositivity
- Cirrhosis of any origin, and alcoholic or non alcoholic steato-hepatitis, either proven histologically or suspected
- Hypertension with a resting systolic blood pressure > 140 or a resting diastolic blood pressure > 90 mm despite adequate antihypertensive treatment
- Any cardiac, pulmonary, thyroid, renal, hepatic, gastrointestinal, neurological (central or peripheral) disease requiring therapy and considered as significant by the investigator or a severe disorder of hemostasis
- Any serious illness requiring systemic treatment and/or hospitalization until the patient either completes therapy or is clinically stable on therapy, in the opinion of the principal investigator, for at least 30 days prior to study entry
- Pregnant or lactating women. Women of childbearing potential must have a negative serum or urine pregnancy test at study entry
- Refusal or inability to practice contraception regardless of the gender of the patient
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CYT107
repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
|
repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
|
No Intervention: Control
Control arm with possible CYT107 injection after 12 months of study participation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To study the biological activity and safety of repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months.
Time Frame: 24 months
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To characterize CYT107 Pharmacokinetics (PK) / Pharmacodynamics (PD)
Time Frame: 24 months
|
24 months
|
To characterize the key immuno-pharmacological effects
Time Frame: 24 months
|
24 months
|
To assess CYT107 effect on HIV-induced chronic systemic immune hyper-activation and its consequences
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CLI-107-14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on CYT107
-
National Institute of Allergy and Infectious Diseases...TerminatedIdiopathic CD4+ T-LymphocytopeniaUnited States
-
Cytheris SATerminated
-
RevimmuneC.R.O. ReSolution Latin America S.A.TerminatedCOVID-19 | LymphocytopeniaBrazil
-
RevimmuneM.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Cancer Research... and other collaboratorsTerminatedCOVID-19 | LymphocytopeniaUnited States
-
RevimmuneUniversity Hospital, Limoges; Amarex Clinical ResearchTerminatedCOVID-19 | LymphocytopeniaFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); RevimmuneWithdrawnRecombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood TransplantationUmbilical Cord Blood Transplant
-
Cytheris, Inc.CompletedAML | MDS | CMLUnited States
-
RevimmuneWashington University School of MedicineTerminatedMycobacterium Infections, NontuberculousUnited States
-
RevimmuneWashington University School of Medicine; Amarex Clinical ResearchTerminatedCOVID-19 | LymphocytopeniaUnited States
-
RevimmuneAmarex Clinical ResearchTerminatedCOVID-19 | LymphocytopeniaUnited Kingdom